KR930701175A - 인체 전립선 아데노카르시노마의 치료방법 - Google Patents

인체 전립선 아데노카르시노마의 치료방법

Info

Publication number
KR930701175A
KR930701175A KR1019920703380A KR920703380A KR930701175A KR 930701175 A KR930701175 A KR 930701175A KR 1019920703380 A KR1019920703380 A KR 1019920703380A KR 920703380 A KR920703380 A KR 920703380A KR 930701175 A KR930701175 A KR 930701175A
Authority
KR
South Korea
Prior art keywords
treat
human prostate
prostate adenocarcinoma
alpha
reductase inhibiting
Prior art date
Application number
KR1019920703380A
Other languages
English (en)
Other versions
KR100209825B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24173248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR930701175(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of KR930701175A publication Critical patent/KR930701175A/ko
Application granted granted Critical
Publication of KR100209825B1 publication Critical patent/KR100209825B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019920703380A 1990-06-27 1991-06-21 인체 전립선 아데노카르시노마의 치료용 약제조성물 KR100209825B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/544,709 US5300294A (en) 1990-06-27 1990-06-27 Method of treating prostatic adenocarcinoma
US544709 1990-06-27
PCT/US1991/004508 WO1992000010A1 (en) 1990-06-27 1991-06-21 Method of treating human prostatic adenocarcinoma

Publications (2)

Publication Number Publication Date
KR930701175A true KR930701175A (ko) 1993-06-11
KR100209825B1 KR100209825B1 (ko) 1999-07-15

Family

ID=24173248

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920703380A KR100209825B1 (ko) 1990-06-27 1991-06-21 인체 전립선 아데노카르시노마의 치료용 약제조성물

Country Status (15)

Country Link
US (2) US5300294A (ko)
EP (1) EP0536282B1 (ko)
JP (5) JP2702280B2 (ko)
KR (1) KR100209825B1 (ko)
AT (1) ATE151635T1 (ko)
AU (1) AU650033B2 (ko)
CA (1) CA2084775C (ko)
DE (1) DE69125714T2 (ko)
DK (1) DK0536282T3 (ko)
ES (1) ES2100952T3 (ko)
GR (1) GR3024064T3 (ko)
HK (1) HK1006412A1 (ko)
IE (1) IE81134B1 (ko)
WO (1) WO1992000010A1 (ko)
ZA (1) ZA914919B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5710275A (en) * 1992-05-20 1998-01-20 Merck & Co., Inc. 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
CA2135167A1 (en) * 1992-05-20 1993-11-25 Donald W. Graham New 17-ester, amide, and ketone derivatives of 3-oxo-4- azasteroids as 5a-reductase inhibitors
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
CN1133005A (zh) * 1993-09-03 1996-10-09 史密丝克莱恩比彻姆公司 稳定的片剂
US5763490A (en) * 1994-09-20 1998-06-09 University Of South Carolina Treating prostate cancer with tartrate ions
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5629007A (en) * 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5635197A (en) * 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
JPH09172979A (ja) * 1995-12-27 1997-07-08 Ajinomoto Co Inc 新規リン酸アミノ酸複合塩及び制酸剤を含有する反すう動物用飼料添加組成物
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
JP2007526913A (ja) * 2004-01-28 2007-09-20 アンドロサイエンス コーポレイション ステロイド依存性の遺伝子活性化経路の異なる段階を標的とする阻害剤の組み合わせによる抗アンドロゲン活性の増強およびその使用
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
AU2008205312B2 (en) 2007-01-08 2013-11-21 Annji Pharmaceutical Co., Ltd. Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
EP2175726A4 (en) 2007-07-31 2011-01-05 Androscience Corp COMPOSITIONS WITH ANDROGEN RECEPTOR DERIVATIVES AND METHOD FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF SKIN DISEASES OR HAIR LOSS
JP2012516900A (ja) 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ，インク． ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
WO2014153215A1 (en) 2013-03-14 2014-09-25 University Of Maryland,Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
AU2014306698A1 (en) 2013-08-12 2016-01-28 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
JPS63203625A (ja) * 1987-02-19 1988-08-23 Kao Corp ５α−リダクタ−ゼ阻害剤
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma

Also Published As

Publication number Publication date
GR3024064T3 (en) 1997-10-31
JP2007063296A (ja) 2007-03-15
ZA914919B (en) 1992-07-29
US5496556A (en) 1996-03-05
ATE151635T1 (de) 1997-05-15
JP2002308776A (ja) 2002-10-23
DE69125714D1 (de) 1997-05-22
JP2702280B2 (ja) 1998-01-21
WO1992000010A1 (en) 1992-01-09
EP0536282A4 (en) 1993-05-05
US5300294A (en) 1994-04-05
JPH05508155A (ja) 1993-11-18
EP0536282A1 (en) 1993-04-14
IE81134B1 (en) 2000-03-22
JPH1081625A (ja) 1998-03-31
KR100209825B1 (ko) 1999-07-15
ES2100952T3 (es) 1997-07-01
JP2000309536A (ja) 2000-11-07
EP0536282B1 (en) 1997-04-16
HK1006412A1 (en) 1999-02-26
CA2084775A1 (en) 1991-12-28
DK0536282T3 (da) 1997-10-27
DE69125714T2 (de) 1997-10-23
AU8207691A (en) 1992-01-23
IE912233A1 (en) 1992-01-01
CA2084775C (en) 2003-04-15
AU650033B2 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
KR930701175A (ko) 인체 전립선 아데노카르시노마의 치료방법
DK1203770T3 (da) Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme
SE8104624L (sv) Anvendning av kombinationen av en aromatashemmare med ett antindrogent medel for profylax och terapi av prostatahyperaplasi
ES2019942B3 (es) Tratamiento de formaciones subterraneas que contienen hierro.
EP0667769A4 (en) USE OF SPECIFIC ALPHA-1C COMPOUNDS IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA.
NO20044458L (no) Anvendelse av en ringsystemforbindelse for fremstilling av et medikament
SE7813276L (sv) Forfarande for deodorisering av slam, speciellt avloppsslam
ES2118414T3 (es) Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
DK0724592T3 (da) 16-substitueret-4-aza-androstan-5alfa-reduktaseisozym-1-inhibitorer
ZA871860B (en) Transglutaminase inhibitors
ES2105774T3 (es) Procedimiento de tratamiento de la alopecia androgena con inhibidores de la 5-alfa reductasa.
FI820115L (fi) Tetrahydronaftalen- och indanfoereningar
DE69218200D1 (de) Behandlung von leberkrebs
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
TW366338B (en) Arylalkoxyphenoxy-imidazoline compounds
JPS53142044A (en) Method of treating drainage
JPS5434552A (en) Method of treating excess sludge
SU747106A1 (ru) Способ огневой проработки канала
ES2120573T3 (es) 24-epi-1-alfa-hidroxivitamina d2 para tratar la osteoporosis.
ES218755U (es) Mampara decorativa para baños.
JPS53114254A (en) Method for biological denitrification of night soil waste water
JPS5411036A (en) Gold-plated wristwatch cash

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080331

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee